Skip to content
OpenCapital
Get started

QuidelOrtho Corporation QDEL Additions / (Releases)

Additions / (Releases) at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$832.61M-51.4%
Enterprise value$3.8B-20.1%
P/S0.3×-0.3×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%—

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease.

The official record: QuidelOrtho Corporation’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's additions / (releases).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's additions / (releases)?
QuidelOrtho Corporation (QDEL) reported additions / (releases) of $137.53M in Q4 2025.
How has QuidelOrtho Corporation's additions / (releases) changed year-over-year?
QuidelOrtho Corporation's additions / (releases) increased by 13.1% year-over-year, from $121.55M to $137.53M.
What is the long-term trend for QuidelOrtho Corporation's additions / (releases)?
Over 2 years (2023 to 2025), QuidelOrtho Corporation's additions / (releases) has grown at a 5.6% compound annual growth rate (CAGR), from $493.5M to $550.1M.
What does additions / (releases) mean?
Reflects the net additions or releases to the allowance for doubtful accounts during the reporting period. It serves as a key indicator of management's assessment of credit risk and the potential for future uncollectible customer receivables.